Clinical Trial Update: Safety, Tolerability and Immunogenicity of a Maternal Respiratory Syncytial Virus (RSV) Vaccine (MKK900) in Healthy Adult Women [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, tolerability, and immunogenicity of MKK900, a maternal respiratory syncytial virus vaccine, in healthy adult women; trial statu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• MKK900

Snippet

Sponsor: MAXVAX Biotechnology Limited Liability Company | Conditions: Respiratory Syncytial Virus (RSV) | Phase 1 | Status: NOT_YET_RECRUITING